我国药品抽检结果信息公开现状分析与建议  

Current Status Analysis and Suggestions on the Results Disclosure of Drug Sampling and Testing in China

作　　者：朱炯[1] 刘文[1] 王胜鹏 王翀[1] 胡增峣 ZHU Jiong;LIU Wen;WANG Sheng-peng;WANG Chong;HU Zeng-yao(National Institute for Food and Drug Control,Beijing 102629,China;National Medical Products Administration,Beijing 100037,China)

机构地区：[1]中国食品药品检定研究院,北京102629 [2]国家药品监督管理局,北京100037

出　　处：《中国药学杂志》2020年第18期1553-1558,共6页Chinese Pharmaceutical Journal

摘　　要：目的为完善药品抽检结果信息公开提供参考。方法通过文献资料和信息公开措施研究,结合案例对我国药品抽检结果信息公开的历史沿革、公开形式、公开现状及意义等进行分析,提出完善建议。结果与结论抽检结果信息公开有助于提升政府公信力、保障公众知情权、震慑不法企业和助推药品质量提升,建议药监部门借鉴美国食品药品监督管理局(FDA)经验提高信息公开的法律地位,加强时效性、成果转化、舆情监测,并在企业信用修复后将企业信息从公开环境中移除,同时建议社会各界正确认识并理性对待抽检信息公开内容,以完善药品抽检结果信息公开,促进药品质量安全的社会共建共治。OBJECTIVE To provide a reference to improve the information disclosure of drug sampling and testing.METHODS Through literature and information disclosure measures research,combined with examples,the historical evolution,disclosure form,disclosure status,and significance of the drug sampling and testing results disclosure in China was analyzed,suggestions was made.RESULTS AND CONCLUSION The disclosure of drug sampling and testing results are helpful to improve the government′s credibility,protect the public′s right to know,deter illegal enterprises and promote the improvement of drug quality.It is suggested that the drug regulatory department learn from the FDA′s experience to improve the legal status of information disclosure,strengthen timeliness,transform results,monitor public opinion and remove the enterprise information from public environment after credit repair,and all circles of society correctly understand and rationally treat the information disclosure content,in order to improve the information disclosure of drug sampling and testing and promote the social co-construction and co-governance of drug quality and safety.

关 键 词：药品抽检 信息公开 现状 

分 类 号：R95[医药卫生—药学]